NCT03950271View on ClinicalTrials.gov

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

January 31, 2024

Study Completion Date

December 31, 2026

Conditions
Gastric Cancer
Interventions
DRUG

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine

"1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles."

Trial Locations (1)

450008

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT03950271 - SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter